» Articles » PMID: 36551936

Disclosure of Genetic Risk Factors for Alzheimer's Disease to Cognitively Healthy Individuals-From Current Practice Towards a Personalised Medicine Scenario

Overview
Journal Biomedicines
Date 2022 Dec 23
PMID 36551936
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a genetically complex disorder. In addition to the relatively small number of pathogenic variants causing autosomal dominant AD, many others have been associated with the much more common sporadic form. The E4 allele of the Apolipoprotein E () is the first discovered genetic risk factor for AD. In addition, more than 70 genetic risk loci contributing to AD have been identified. Current guidelines do not recommend AD susceptibility genetic testing in cognitively healthy adults because the implications for clinical care are limited. However, secondary prevention clinical trials of disease-modifying therapies enrol individuals based on genetic criteria, and participants are often informed of testing results. Moreover, the availability of direct-to-consumer genetic testing allows individuals to learn their own AD genetic risk profile without medical supervision. A number of research protocols for AD susceptibility genetic testing have been proposed. In Italy, disclosure processes and protocols beyond those developed for inherited dementia have not been established yet. We reviewed the literature on the current practice and clinical issues related to disclosing AD genetic risk to cognitively healthy individuals and provide suggestions that may help to develop specific guidelines at the national level.

Citing Articles

The impact of rare genetic variants on Alzheimer disease.

De Deyn L, Sleegers K Nat Rev Neurol. 2025; 21(3):127-139.

PMID: 39905212 DOI: 10.1038/s41582-025-01062-1.


Association of Apolipoprotein E (APOE) Polymorphisms With Serological Lipid and Inflammatory Markers.

Krishnamurthy H, Rajavelu I, Reddy S, Pereira M, Jayaraman V, Krishna K Cureus. 2024; 16(5):e60721.

PMID: 38903305 PMC: 11187349. DOI: 10.7759/cureus.60721.


Apolipoprotein E in Alzheimer's disease trajectories and the next-generation clinical care pathway.

Narasimhan S, Holtzman D, Apostolova L, Cruchaga C, Masters C, Hardy J Nat Neurosci. 2024; 27(7):1236-1252.

PMID: 38898183 DOI: 10.1038/s41593-024-01669-5.


The Return of Biomarker Results in Research: Balancing Complexity, Precision, and Ethical Responsibility.

Robillard J, Masellis M, Martin S, Khachaturian A, Dixon R J Alzheimers Dis. 2024; 97(3):1083-1090.

PMID: 38306053 PMC: 10836546. DOI: 10.3233/JAD-230359.


Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study.

Waterink L, Masselink L, van der Lee S, Visser L, Cleutjens S, Van Der Schaar J Alzheimers Res Ther. 2024; 16(1):1.

PMID: 38167083 PMC: 10759504. DOI: 10.1186/s13195-023-01364-w.


References
1.
Dourlen P, Kilinc D, Malmanche N, Chapuis J, Lambert J . The new genetic landscape of Alzheimer's disease: from amyloid cascade to genetically driven synaptic failure hypothesis?. Acta Neuropathol. 2019; 138(2):221-236. PMC: 6660578. DOI: 10.1007/s00401-019-02004-0. View

2.
Ongaro G, Brivio E, Cincidda C, Oliveri S, Spinella F, Steinberger D . Genetic testing users in Italy and Germany: Health orientation, health-related habits, and psychological profile. Mol Genet Genomic Med. 2022; 10(3):e1851. PMC: 8922951. DOI: 10.1002/mgg3.1851. View

3.
Baker E, Escott-Price V . Polygenic Risk Scores in Alzheimer's Disease: Current Applications and Future Directions. Front Digit Health. 2021; 2:14. PMC: 8521998. DOI: 10.3389/fdgth.2020.00014. View

4.
Pitini E, De Vito C, Marzuillo C, DAndrea E, Rosso A, Federici A . How is genetic testing evaluated? A systematic review of the literature. Eur J Hum Genet. 2018; 26(5):605-615. PMC: 5945588. DOI: 10.1038/s41431-018-0095-5. View

5.
Ranson J, Rittman T, Hayat S, Brayne C, Jessen F, Blennow K . Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. Alzheimers Res Ther. 2021; 13(1):169. PMC: 8507172. DOI: 10.1186/s13195-021-00895-4. View